Compare ASPI & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASPI | RLMD |
|---|---|---|
| Founded | 2021 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 475.3M | 524.9M |
| IPO Year | 2022 | 2012 |
| Metric | ASPI | RLMD |
|---|---|---|
| Price | $4.04 | $5.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $12.00 | ★ $12.40 |
| AVG Volume (30 Days) | ★ 4.0M | 1.6M |
| Earning Date | 04-10-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.28 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $23,849,000.00 | $13,070.00 |
| Revenue This Year | $68.41 | N/A |
| Revenue Next Year | $126.69 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 475.48 | 154.83 |
| 52 Week Low | $3.51 | $0.55 |
| 52 Week High | $14.49 | $8.00 |
| Indicator | ASPI | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 38.29 | 35.17 |
| Support Level | $3.86 | $4.85 |
| Resistance Level | $5.88 | $7.28 |
| Average True Range (ATR) | 0.32 | 0.39 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 30.40 | 13.01 |
ASP Isotopes Inc is a materials company focused on producing and commercializing enriched isotopes for the nuclear medicine, healthcare, green energy, and quantum computing industries. Currently, the company has three operating segments: (i) nuclear fuels, (ii) specialist isotopes and related services, and (iii) construction services. Using proprietary technology-the Aerodynamic Separation Process (ASP)-the company enriches isotopes in South Africa, targeting high-value, low-volume markets to reduce reliance on foreign supply chains. Geographically, the company operates in South Africa, Hong Kong and United States generating key revenue from the Hong Kong region.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.